Upregulation of brain cytosolic and lysosomal GCase activity may reduce alpha-synuclein (aSyn) levels, mediating a neuroprotective effect in patients with PD, both with and without GBA mutations [25, 26]. This evidence concerns the gene GBA1 and Parkinson disease.